Kane Biotech Inc. (CVE:KNE – Get Free Report) reached a new 52-week low on Tuesday . The stock traded as low as C$0.02 and last traded at C$0.03, with a volume of 421000 shares traded. The stock had previously closed at C$0.03.
Kane Biotech Stock Down 16.7%
The firm has a fifty day simple moving average of C$0.03 and a 200 day simple moving average of C$0.03. The company has a debt-to-equity ratio of -135.17, a quick ratio of 0.39 and a current ratio of 0.45. The company has a market cap of C$5.13 million, a PE ratio of -2.50 and a beta of 1.06.
About Kane Biotech
Kane Biotech Inc, a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, an antimicrobial wound gel platform; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine for treating wounds and otic infections. It offers revyve, an antimicrobial wound gel; and shampoos, shampoo bars, and scalp detoxifiers under the DermaKB brand.
Featured Articles
- Five stocks we like better than Kane Biotech
- PriceSmart Stock Eyes $220 as Chile Expansion Fuels Growth
- Dollar Tree’s Turnaround Is Starting to Take Root
- Why Levi’s Digital Strategy Is Paying Off in a Big Way
- Constellation Brands: Beer Growth and Buybacks Mask Stock’s Slump
Receive News & Ratings for Kane Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kane Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
